Chronic Lymphocytic Leukemia Research

Chronic lymphocytic leukemia (CLL) is a slow-progressing blood cancer in which the body accumulates abnormal B-lymphocytes, and researchers studying its genetics aim to understand how specific genomic alterations — such as mutations in the tumor suppressor gene TP53 and rearrangements in immunoglobulin genes — determine how aggressively the disease behaves in individual patients. These findings have direct clinical consequences: certain mutations predict resistance to standard therapies, driving the development of targeted agents like ibrutinib, a BTK inhibitor that blocks a key survival signal in malignant cells, and rituximab, an antibody that marks those cells for immune destruction. A central open question is why some patients develop resistance to BTK inhibitors over time, and how the genomic landscape of related conditions like Waldenström macroglobulinemia overlaps with or diverges from CLL in ways that might inform shared or distinct treatment strategies. Identifying reliable prognostic markers that can guide treatment selection from the outset — sparing patients ineffective therapies while improving long-term outcomes — remains one of the most active directions in the field.

Works

99,722

Total citations

1,205,139

Keywords

Chronic Lymphocytic LeukemiaGenomic AberrationsBTK InhibitorsRituximabIbrutinibPrognostic Factors